Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Director · President, CEO, & Director | July 30, 2026 | August 03, 2026 |
| Axonics, Inc.AXNX · Entity 86004 | Director | November 15, 2024 | November 15, 2024 |
| Inspire Medical Systems, Inc.INSP · Entity 1186 | Director | July 20, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 774,434 |
Ending reported balance
After 2026-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-30 · Gift · Disposed 700 · Balance 778,434 F1: No consideration was received in connection with this gift to the reporting person's parent. Row 2 · 2026-07-30 · Gift · Disposed 4,000 · Balance 774,434 F2: No consideration was received in connection with this charitable gift. |
| Common StockSEC Table I · non-derivative | IndirectHeld by reporting person's children | 14,310 |
Reported balance
Holding disclosure · report date 2026-07-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 14,310 F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by reporting person's parent | 2,950 |
Reported balance
Holding disclosure · report date 2026-07-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,950 F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by reporting person's sibling | 1,000 |
Reported balance
Holding disclosure · report date 2026-07-30 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: No consideration was received in connection with this gift to the reporting person's parent.
F2: No consideration was received in connection with this charitable gift.
F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.
Axonics, Inc.
Report date November 15, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Disposition to issuer · Disposed 17,861 · Balance 0 F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.10 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-15 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.85 · Expires 2029-02-27 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.
Inspire Medical Systems, Inc.
Report date July 20, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,631 |
Reported balance
After 2026-07-20 transaction · row 1
1 source rowRow 1 · 2026-07-20 · Grant · Acquired 5,631 · Balance 5,631 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in three equal annual installments on the first three anniversaries of the date of grant, subject to the Reporting Person's continued service on the board of directors of the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in three equal annual installments on the first three anniversaries of the date of grant, subject to the Reporting Person's continued service on the board of directors of the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $50.00 | $1,250,000.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 20:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050289 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| August 24, 2020 Filed Aug 27, 2020 00:18 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005680 · primarydocument.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:36 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 357 | $28.11 | $10,035.27 |
DisclosureSEC source: 0001209191-20-040352 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,504 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 1, 2020, which was the first trading day of the applicable offering period. The closing price on January 1, 2020 was $33.07. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-028847 · doc4.xml · derivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $47.00 | $1,175,000.00 |
DisclosureSEC source: 0001209191-20-028847 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,147 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-028847 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-028847 · doc4.xml · derivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $46.00 | $1,150,000.00 |
DisclosureSEC source: 0001209191-20-028847 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,147 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $46.02 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-028847 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| May 08, 2020 Filed May 8, 2020 21:02 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-027973 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| May 08, 2020 Filed May 8, 2020 21:02 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $45.00 | $1,125,000.00 |
DisclosureSEC source: 0001209191-20-027973 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,147 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| May 08, 2020 Filed May 8, 2020 21:02 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-027973 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:15 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 143,576 | $38.42 | $5,516,189.92 |
DisclosureSEC source: 0001209191-20-015124 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,147 F2 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:15 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 31,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015124 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,723 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 13:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-009883 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 13:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $44.00 | $1,100,000.00 |
DisclosureSEC source: 0001209191-20-009883 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 13:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-009883 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 13:40 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-009477 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 13:40 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $43.00 | $1,075,000.00 |
DisclosureSEC source: 0001209191-20-009477 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 13:40 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-009477 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 13:08 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-008569 · doc4.xml · derivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 13:08 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $42.00 | $1,050,000.00 |
DisclosureSEC source: 0001209191-20-008569 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 13:08 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-008569 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 13:08 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-008569 · doc4.xml · derivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 13:08 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $41.00 | $1,025,000.00 |
DisclosureSEC source: 0001209191-20-008569 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 13:08 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-008569 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 12:35 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-005720 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: These options were granted on November 1, 2012 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 12:35 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $40.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-20-005720 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 12:35 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-005720 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 12:22 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-003566 · doc4.xml · derivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: These options were granted on November 1, 2012 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 12:22 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $35.00 | $875,000.00 |
DisclosureSEC source: 0001209191-20-003566 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 12:22 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-003566 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 12:22 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-003566 · doc4.xml · derivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: These options were granted on November 1, 2012 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 12:22 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $34.00 | $850,000.00 |
DisclosureSEC source: 0001209191-20-003566 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 12:22 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $5.91 | $147,750.00 |
DisclosureSEC source: 0001209191-20-003566 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 12:36 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,546 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-001473 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 23,546 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: These options were granted on November 1, 2012 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 12:36 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 23,546 | $33.00 | $777,018.00 |
DisclosureSEC source: 0001209191-20-001473 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.00 to $33.01 per share. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 12:36 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 23,546 | $5.91 | $139,156.86 |
DisclosureSEC source: 0001209191-20-001473 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:13 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 387 | $25.99 | $10,058.13 |
DisclosureSEC source: 0001209191-20-000861 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,490 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended December 31, 2019. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2019, which was the first trading day of the applicable offering period. The closing price on July 1, 2019 was $30.58. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 11:50 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-048988 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,103 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| August 22, 2019 Filed Aug 27, 2019 00:25 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001562180-19-004496 · primarydocument.xml · derivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-08-22 F1 · derivative.exercise_date: The shares subject to the option will vest in full on August 18, 2020. Read SEC document |
| August 22, 2019 Filed Aug 27, 2019 00:25 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004496 · primarydocument.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:40 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,454 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-19-044273 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,546 Underlying: Common Stock · 1,454 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: These options were granted on November 1, 2012 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:40 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 1,454 | $33.00 | $47,982.00 |
DisclosureSEC source: 0001209191-19-044273 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,103 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:40 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 1,454 | $5.91 | $8,593.14 |
DisclosureSEC source: 0001209191-19-044273 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 12:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-19-041875 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: These options were granted on November 1, 2012 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 12:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $32.00 | $800,000.00 |
DisclosureSEC source: 0001209191-19-041875 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,103 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $32.00 to $32.01 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.